The KLOW peptide stack combines GHK-Cu, BPC-157, TB-500, and KPV into an experimental multi-target formulation. While rodent and in vitro studies show dist
Read more The KLOW Peptide Stack: Preclinical Data vs. Human Evidence Gaps
PE-22-28 is a synthetic heptapeptide derived from the natural peptide spadin. Both target the TREK-1 potassium channel, but preclinical evidence shows PE-2
Read more PE-22-28 vs. Spadin: Comparative Evidence in TREK-1 Potassium Channel Research
Eloralintide (LY3841136) is an investigational, long-acting selective amylin receptor agonist in clinical development for obesity management. Phase 2 human
Read more Eloralintide and Amylin Receptor Agonism: What the Clinical Research Shows
TB-500 and thymosin beta-4 are frequently conflated, yet they are distinct molecules. This scientific review examines their structural divergence, actin-bi
Cagrilintide is an investigational, long-acting dual amylin and calcitonin receptor agonist. This scientific review examines its receptor pharmacology, hum
Read more Cagrilintide: Human Clinical Trials, Pharmacology, and Evidence Limitations
PT-141 (bremelanotide) is a synthetic melanocortin receptor agonist that acts within the central nervous system. By activating hypothalamic MC3R and MC4R p
Read more PT-141: Central Nervous System Mechanism and Melanocortin Signaling